FDC in nanotechnology

[1]  R. Tekade,et al.  Clinical Aspects and Regulatory Requirements for Nanomedicines , 2019, Basic Fundamentals of Drug Delivery.

[2]  B. Dey,et al.  Liposome: a carrier for effective drug delivery , 2020 .

[3]  Willis,et al.  Ligand-targeted liposomes. , 1998, Advanced drug delivery reviews.

[4]  S. Vyas,et al.  Emergence of novel targeting systems and conventional therapies for effective cancer treatment , 2021 .

[5]  Gert Storm,et al.  Liposomes: The Science and the Regulatory Landscape , 2015 .

[6]  Margaret A. Hamburg,et al.  FDA's Approach to Regulation of Products of Nanotechnology , 2012, Science.

[7]  S. Gaspani.  Access to liposomal generic formulations: beyond AmBisome and Doxil/Caelyx , 2013 .

[8]  C. L. Ventola,et al.  Progress in Nanomedicine: Approved and Investigational Nanodrugs. , 2017, P & T : a peer-reviewed journal for formulary management.

[9]  A. Bangham,et al.  Diffusion of univalent ions across the lamellae of swollen phospholipids. , 1965, Journal of molecular biology.

[10]  Debbie Jordan.  An overview of the Common Technical Document (CTD) regulatory dossier , 2014 .

[11]  C Shad Thaxton,et al.  Nanoparticle therapeutics: FDA approval, clinical trials, regulatory pathways, and case study. , 2011, Methods in molecular biology.

[12]  Wahid Khan,et al.  Liposomal Formulations in Clinical Use: An Updated Review , 2017, Pharmaceutics.

[13]  J. Molzon.  The Common Technical Document: the changing face of the New Drug Application , 2003, Nature Reviews Drug Discovery.

[14]  J. Lovrić,et al.  Nanotherapeutics in the EU: an overview on current state and future directions , 2014, International journal of nanomedicine.

[15]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[16]  Kim Nordfjeld,et al.  Creating eCTD Applications , 2006 .

[17]  Y. Barenholz,et al.  Annals of the New York Academy of Sciences Nanomedicines: Addressing the Scientific and Regulatory Gap , 2022 .

[18]  S. Mitragotri,et al.  Nanoparticles in the clinic , 2016, Bioengineering & translational medicine.

[19]  Ajmer Singh Grewal,et al.  Recent Updates on Nanomedicine Based Products: Current Scenario and Future Opportunities , 2018, Applied Clinical Research, Clinical Trials and Regulatory Affairs.

[20]  Susan Wijnhoven,et al.  Risk assessment frameworks for nanomaterials: Scope, link to regulations, applicability, and outline for future directions in view of needed increase in efficiency , 2018 .

[21]  D. Papahadjopoulos,et al.  Liposomes revisited , 1995, Science.

[22]  D. Grainger,et al.  Lyophilized liposome-based parenteral drug development: Reviewing complex product design strategies and current regulatory environments. , 2019, Advanced drug delivery reviews.

[23]  N. Sadrieh,et al.  Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. , 2011, Methods in molecular biology.

[24]  N. Nishiyama,et al.  General considerations regarding the in vitro and in vivo properties of block copolymer micelle products and their evaluation. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Soodabeh Davaran,et al.  Liposome: classification, preparation, and applications , 2013, Nanoscale Research Letters.

[27]  Kristofer J. Thurecht,et al.  Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date , 2016, Pharmaceutical Research.

[28]  T. Faunce.  Nanotherapeutics: new challenges for safety and cost‐effectiveness regulation in Australia , 2007, The Medical journal of Australia.

[29]  Qiang Zhang,et al.  Development of liposomal formulations: From concept to clinical investigations , 2013 .